GlobeNewswire

ADC Therapeutics Announces Presentations at the 15th International Conference on Malignant Lymphoma

Share

Three oral presentations and one poster presentation

Pyrrolobenzodiazepine-based antibody drug conjugates demonstrate potential for the treatment of relapsed or refractory lymphomas as single agents and in combination therapies

LAUSANNE, Switzerland, June 12, 2019 (GLOBE NEWSWIRE) -- ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of antibody drug conjugates (ADCs), today announced that data on ADCT-402 (loncastuximab tesirine) and ADCT-301 (camidanlumab tesirine) have been selected for four presentations at the 15th International Conference on Malignant Lymphoma (15-ICML), which is being held June 18-22, 2019, in Lugano, Switzerland.

Jay Feingold, MD, PhD, Chief Medical Officer and Senior Vice President of Clinical Development at ADC Therapeutics, said, “We are pleased to be presenting compelling data at 15-ICML from our 183-patient Phase I clinical trial of ADCT-402 in relapsed or refractory B-cell lymphoma (including 139 patients with diffuse large B-cell lymphoma), as well as our 128-patient Phase I clinical trial of ADCT-301 in relapsed or refractory Hodgkin and non-Hodgkin lymphoma (including 77 patients with Hodgkin lymphoma). Based on these data, ADCT-402 is now in an ongoing pivotal Phase II trial and we plan to commence a pivotal Phase II trial of ADCT-301 later this summer. In addition, new preclinical studies highlight the potential of these novel ADCs for the treatment of lymphomas as both single agents and in combination with other targeted drugs. The data reinforce our position as a leader in the development of next generation PBD-based ADCs and the strength of our hematology franchise, which now also includes ADCT-602 in a Phase I clinical trial for acute lymphoblastic leukemia.”

Oral Presentations

Title: Analysis of Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) by Demographic and Clinical Characteristics in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Abstract Number: 054
Session: Session 4 – Treatment with Novel Antibodies
Date/Time: Thursday, June 20, 16:25 CEST
Location: Room A, Cinema Corso Auditorium and Aula Magna
Presenter: John Radford MD, FRCP, Department of Medical Oncology, The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK

Title: Analysis of Clinical Determinants Driving Safety and Efficacy of Camidanlumab Tesirine (ADCT-301, Cami) in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL)
Abstract Number: 055
Session: Session 4 – Treatment with Novel Antibodies
Date/Time: Thursday, June 20, 16:40 CEST
Location: Room A, Cinema Corso Auditorium and Aula Magna
Presenter: Graham Collins, MB, BS, DPhil, Department of Clinical Haematology, Oxford University Hospitals, NHS Foundation Trust, Oxford, UK

Title: The Antibody-Drug Conjugate (ADC) Loncastuximab Tesirine (ADCT-402) Targeting CD19 Shows Strong In Vitro Anti-Lymphoma Activity Both as Single Agents and In Combination
Abstract Number: 084
Session: Focus On Non-Clinical New Drugs
Date/Time: Thursday, June 20, 17:55 CEST
Location: Auditorium (USI Universitá)
Presenter: Chiara Tarantelli, PhD, Università della Svizzera italiana, Institute of Oncology Research

Poster Presentation

Title: The Anti-CD25 Antibody-Drug Conjugate Camidanlumab Tesirine (ADCT-301) Presents a
Strong Preclinical Activity Both as Single Agent and In Combination in Lymphoma Cell Lines
Poster Number: 270
Session: Poster Session
Date/Time: Wednesday, June 19, 12:00-17:00 CEST; Thursday, June 20, 9:00-17:00 CEST; Friday, June 21, 9:00-18:30 CEST
Location: Marquee
Presenter: Filippo Spriano, PhD, Institute of Oncology Research

Abstracts are available on the 15-ICML web site: www.lymphcon.ch

About ADCT-402

ADCT-402 (loncastuximab tesirine) is an antibody drug conjugate (ADC) composed of a humanized monoclonal antibody that binds to human CD19, conjugated through a linker to a pyrrolobenzodiazepine (PBD) dimer toxin. Once bound to a CD19-expressing cell, ADCT-402 is internalized into the cell where enzymes release the PBD-based warhead. CD19 is a clinically validated target for the treatment of B-cell malignancies. The PBD-based warhead has the ability to form highly cytotoxic DNA interstrand cross-links, blocking cell division and resulting in cell death. ADCT-402 is being evaluated in a pivotal Phase II clinical trial in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) (NCT03589469), a Phase Ib trial in combination with ibrutinib in patients with R/R DLBCL or mantle cell lymphoma (MCL) (NCT03684694) and a Phase Ib trial in combination with durvalumab in patients with R/R DLBCL, MCL or follicular lymphoma (NCT03685344). The U.S. Food and Drug Administration granted orphan drug designation to ADCT-402 for the treatment of relapsed or refractory DLBCL and MCL.

About ADCT-301

ADCT-301 (camidanlumab tesirine) is an antibody drug conjugate (ADC) composed of a monoclonal antibody that binds to CD25 (HuMax®-TAC, licensed from Genmab A/S), conjugated to the pyrrolobenzodiazepine (PBD) dimer payload tesirine. Once bound to a CD25-expressing cell, ADCT-301 is internalized into the cell where enzymes release the PBD-based warhead. The intra-tumor release of its PBD warhead may cause bystander killing of neighboring tumor cells. In addition, the PBD warhead will trigger immunogenic cell death, which in turn will strengthen the immune response against tumor cells. ADCT-301 is being evaluated in ongoing Phase Ia/Ib clinical trials in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma (NCT02432235), as well as a Phase Ib clinical trial in solid tumors (NCT03621982).

About ADC Therapeutics

ADC Therapeutics SA is an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs) targeting hematological malignancies and solid tumors with significant unmet medical need. The Company’s ADCs are highly targeted biopharmaceutical drugs that combine monoclonal antibodies specific to surface antigens present on particular tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads via a chemical linker. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, in the USA and Europe, and a deep pipeline of other preclinical ADCs in development. ADC Therapeutics reported encouraging clinical data, including manageable tolerability profiles and strong single-agent anti-tumor activity for its 183-patient Phase I trial of ADCT-402 (loncastuximab tesirine) and 128-patient Phase I trial of ADCT-301 (camidanlumab tesirine) in multiple subtypes of lymphoma at the 60th American Society of Hematology (ASH) Annual Meeting. The Company is based in Lausanne (Biopôle), Switzerland and has operations in London, San Francisco and New Jersey. For more information, visit www.adctherapeutics.com.

Investors Contact                                            
Dr. Chris Martin                               
Chief Executive Officer                                 
Chris.martin@adctherapeutics.com Tel.: +41 (0) 21 653 0200

EU Media Contact           
Alexandre Müller            
Dynamics Group              
amu@dynamicsgroup.ch
Tel: +41 (0) 43 268 3231

USA Media Contact
Tony Plohoros
6 Degrees
tplohoros@6degreespr.com
Tel.: +1 908-591-2839  

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Scandinavian Tobacco Group A/S: Indberetning og offentliggørelse af transaktioner udført af person med ledelsesansvar4.6.2020 18:00:00 CESTpressemeddelelse

Selskabsmeddelelse Nr. 15/2020 København, den 4. juni 2020 Indberetning og offentliggørelse af transaktioner udført af person med ledelsesansvar 1. Nærmere oplysninger om personen med ledelsesansvar/personen med nær tilknytning til denne a) Navn Claus Gregersen 2. Årsag til indberetningen a) Stilling/titel Medlem af bestyrelsen b) Første indberetning/ændring Første indberetning 3. Nærmere oplysninger om udstederen, deltageren på markedet for emissionskvoter, auktionsplatformen, auktionsholderen eller den auktionstilsynsførende a) Navn Scandinavian Tobacco Group A/S b) LEI-kode 5299003KG4JS99TRML67 4. Nærmere oplysninger om transaktionen/transaktionerne: gentages for (i) hver type instrument, (ii) hver type transaktion, (iii) hver dato og (iv) hvert sted, hvor der er udført transaktioner a) Beskrivelse af det finansielle instrument, instrumenttypen Identifikationskode Aktier DK0060696300 – STG b) Transaktionens art Køb af aktier c) Pris(er) og mængde(r) Pris(er)Mængde(r)98,8849 aktier98

Scandinavian Tobacco Group A/S: Notification and Public Disclosure of Transactions by Person Discharging Managerial Responsibilities4.6.2020 18:00:00 CESTPress release

Company Announcement No. 15/2020 Copenhagen, 4 June 2020 Notification and Public Disclosure of Transactions by Person Discharging Managerial Responsibilities 1. Information on the person discharging managerial responsibilities/person closely associated a) Name Claus Gregersen 2. Reason for the notification a) Position/title Member of the Board of Directors b) Initial notification/amendment Initial notification 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Scandinavian Tobacco Group A/S b) LEI code 5299003KG4JS99TRML67 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument Identification code Shares DK0060696300 – STG b) Nature of the transaction Purchase of shares c) Price(s) and volume(s) Price(s)Volume(s)98.8

Maha Energy AB (publ) Announce May Production Volumes4.6.2020 17:00:00 CESTPress release

­­­Maha Energy AB (publ) Strandvägen 5A SE-114 51 Stockholm www.mahaenergy.ca Press release Stockholm June 4, 2020 Maha Energy AB (publ) Announce May Production Volumes Production Volumes The Company's aggregate sales production for the month of May totaled 106,2481 barrels of oil and 52.765 million scf of gas for a combined average production of approximately 3,711 BOE/day2, before royalties and taxes. The month of May saw increasing gas sales at Tie as a new gas end-user started taking deliveries allowing for higher oil production. Further at both Tie and Tartaruga stations, oil production was somewhat affected due to temporary surface jet pump maintenance issues which were resolved during the month. Despite the pump issues and continuing Covid-19 movement restrictions, production and off-take volumes in Brazil remain stable. 1 Subject to minor standard industry adjustments at the time of custody transfer. 2 Barrels of oil equivalent ("BOE") conversion ratio of 6,000 scf: 1 bbl is us

Cyber Security 1 AB: CYBER1 Confirms Publication Date for the 2019 Annual Report4.6.2020 16:45:00 CESTPress release

CYBER1 Confirms Publication Date for the 2019 Annual Report London United Kingdom – 04 June 2020, Cyber Security 1 AB (Publ) (“CYBER1”), (Nasdaq:CYB1, OTCQX:CYBNY), has announced a revised publication date of the 9th of June, for the 2019 Annual Report. The change in date brings the 2019 Annual Report publication in line with the Cyber Security 1 AB 2020 AGM, scheduled for Tuesday, 30 June 2020. Shareholders and key stakeholders in the interim may refer to the full year unaudited accounts, through the Q4 2019 report available on our website: www.cyber1.com The annual report once published will be available to view on the CYBER1 website. Certified Adviser Mangold Fondkommission AB is the Company’s Certified Adviser. Telephone: +46 (0)8 5030 1550 E-mail: ca@mangold.se FOR FURTHER INFORMATION, PLEASE CONTACT: Investor Relations Contact: Tim Metcalfe / Zach Cohen CYBER1 Email: cyber1@investor-focus.co.uk ABOUT CYBER1 CYBER1 is engaged in providing cyber resilience solutions and conducts it

Arion Bank: Notification regarding market making agreement4.6.2020 14:48:04 CESTPress release

Reference is made to the Bank´s announcment published on 12 March 2020. Íslandsbanki, which acts as a market maker for shares issued by Arion Bank in Iceland, has today announced that it will no longer exercise its right in the market making agreement that allows them to deviate from the terms of the agreement, regarding the spread and amount. For further information please contact Theodor Fridbertsson, head of Arion Bank’s Investor Relations at ir@arionbanki.is, (+ 354) 856 6760.